Intercept Pharmaceuticals traded at $13.67 this Wednesday June 29th, increasing $0.67 or 5.15 percent since the previous trading session. Looking back, over the last four weeks, Intercept Pharmaceuticals gained 24.48 percent. Over the last 12 months, its price fell by 31.55 percent. Looking ahead, we forecast Intercept Pharmaceuticals to be priced at 13.20 by the end of this quarter and at 12.16 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 14.22 0.22 1.57% -41.70%
Acorda Therapeutics 0.45 -0.01 -2.30% -90.63%
Alnylam Pharmaceuticals 145.43 3.23 2.27% -14.21%
Amgen 245.43 1.92 0.79% 0.69%
Amarin 1.82 -0.03 -1.62% -58.45%
Arrowhead Research 34.56 2.09 6.44% -58.27%
AstraZeneca 11,054.00 268.00 2.48% 27.31%
Biogen 205.23 2.72 1.34% -40.73%
Bluebird Bio 4.58 0.54 13.37% -85.68%
Bristol-Myers Squibb 78.28 -0.42 -0.53% 17.15%
Enanta Pharmaceuticals 46.91 2.36 5.30% 6.59%
Esperion Therapeutics 6.67 0.40 6.38% -68.46%
Galectin Therapeutics 1.25 0 0% -60.94%
Gilead Sciences 62.48 0.27 0.43% -9.27%
GlaxoSmithKline 1,793.00 27.00 1.53% 26.32%
Intercept Pharmaceuticals 13.67 0.67 5.15% -31.55%
Incyte Corp 75.89 0.26 0.34% -9.79%
Ionis Pharmaceuticals 37.56 -0.41 -1.08% -5.84%
Eli Lilly 323.00 5.38 1.69% 40.73%
Moderna Inc 142.81 0.62 0.44% -39.22%
Neurocrine Biosciences 98.46 1.53 1.58% 1.17%
Novartis 81.19 0.05 0.06% -3.71%
PTC Therapeutics 40.40 0.46 1.15% -4.42%
Regeneron Pharmaceuticals 597.62 3.20 0.54% 4.00%
Sangamo BioSciences 4.14 0.05 1.22% -65.41%
Sarepta Therapeutics 77.07 2.40 3.21% -0.86%
Vertex Pharmaceuticals 280.35 4.18 1.51% 38.64%

Indexes Price Day Year
USND 11178 -3.65 -0.03% -22.93%

Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. The Company’s product candidates include Ocaliva (obeticholic or OCA) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. In addition to commercializing OCA for PBC, it is also developing OCA for additional indications, including NASH. The Company is also developing product candidates in various stages of clinical and preclinical development.